Literature DB >> 24030789

Clinical and neurophysiological profile of four German families with spinocerebellar ataxia type 14.

Christos Ganos1, Simone Zittel, Martina Minnerop, Odette Schunke, Christina Heinbokel, Christian Gerloff, Christine Zühlke, Peter Bauer, Thomas Klockgether, Alexander Münchau, Tobias Bäumer.   

Abstract

Spinocerebellar ataxia type 14 (SCA14) is an autosomal-dominant ataxia caused by point mutations of the Protein Kinase C Gamma gene. In addition to slowly progressive cerebellar ataxia, it is characterised by dystonia and myoclonus. With scant neuropathological data and no detailed neurophysiological examinations little is known on extracerebellar consequences of SCA14 related cerebellar pathology. To this end, we here delineate clinical phenomenology and neurophysiology of four German SCA14 families. Detailed clinical examination including ataxia severity evaluation by means of the Scale for the Assessment and Rating of Ataxia (SARA) was carried out in 9 affected family members (mean age 49.8 years ± 14.4 SD). Motor thresholds (MT), the contralateral silent period (CSP), short interval intracortical inhibition (SICI) and intracortical facilitation (ICF), interhemispheric inhibition (IHI) and short afferent inhibition (SAI) were determined using transcranial magnetic stimulation (TMS). Somatosensory evoked potentials (SEP) of the median nerve, and acoustic and visual evoked potentials (AEP, VEP) were also performed. Most patients reported symptoms since early childhood. There was a positive correlation between age and SARA scores (r = .721, P < 0.05). Patients had cerebellar ataxia, mild dystonia (focal, task-specific or segmental), subtle pyramidal signs and myoclonus. SICI increased with increasing conditioning pulse intensities in healthy controls but not in patients. Other neurophysiological parameters did not differ between groups. SCA14 is a slowly progressive ataxia associated with mild dystonia and myoclonus. Reduced SICI reflects abnormalities of intracortical inhibitory circuits.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24030789     DOI: 10.1007/s12311-013-0522-7

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  45 in total

1.  Evidence of widespread impairment of motor cortical inhibition in focal dystonia: a transcranial magnetic stimulation study in patients with blepharospasm and cervical dystonia.

Authors:  Raif Cakmur; Berril Donmez; Fatma Uzunel; Huriye Aydin; Serdar Kesken
Journal:  Adv Neurol       Date:  2004

2.  Motor cortex activation by transcranial magnetic stimulation in ataxia patients depends on the genetic defect.

Authors:  Peter Schwenkreis; Martin Tegenthoff; Katja Witscher; Christian Börnke; Horst Przuntek; Jean-Pierre Malin; Ludger Schöls
Journal:  Brain       Date:  2002-02       Impact factor: 13.501

3.  New mutations in protein kinase Cgamma associated with spinocerebellar ataxia type 14.

Authors:  Stephan Klebe; Alexandra Durr; Alexander Rentschler; Valerie Hahn-Barma; Michael Abele; Naima Bouslam; Ludger Schöls; Pierre Jedynak; Sylvie Forlani; Elodie Denis; Christel Dussert; Yves Agid; Peter Bauer; Christoph Globas; Ullrich Wüllner; Alexis Brice; Olaf Riess; Giovanni Stevanin
Journal:  Ann Neurol       Date:  2005-11       Impact factor: 10.422

4.  Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia.

Authors:  F Gilio; A Currà; C Lorenzano; N Modugno; M Manfredi; A Berardelli
Journal:  Ann Neurol       Date:  2000-07       Impact factor: 10.422

5.  Myoclonic disorders: a practical approach for diagnosis and treatment.

Authors:  Maja Kojovic; Carla Cordivari; Kailash Bhatia
Journal:  Ther Adv Neurol Disord       Date:  2011-01       Impact factor: 6.570

Review 6.  Consensus paper on short-interval intracortical inhibition and other transcranial magnetic stimulation intracortical paradigms in movement disorders.

Authors:  Alfredo Berardelli; Giovanni Abbruzzese; Robert Chen; Michael Orth; Michael C Ridding; Cathy Stinear; Antonio Suppa; Carlo Trompetto; Philip D Thompson
Journal:  Brain Stimul       Date:  2008-07-01       Impact factor: 8.955

7.  Cortical excitability in hereditary motor neuronopathy with pyramidal signs: comparison with ALS.

Authors:  S Vucic; G A Nicholson; M C Kiernan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-01       Impact factor: 10.154

8.  Reduced intracortical facilitation in patients with cerebellar degeneration.

Authors:  J Liepert; K Wessel; P Schwenkreis; P Trillenberg; V Otto; M Vorgerd; J P Malin; M Tegenthoff
Journal:  Acta Neurol Scand       Date:  1998-11       Impact factor: 3.209

9.  Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study.

Authors:  U Ziemann; S Lönnecker; B J Steinhoff; W Paulus
Journal:  Ann Neurol       Date:  1996-09       Impact factor: 10.422

10.  Cortical excitability in DYT-11 positive myoclonus dystonia.

Authors:  Emmanuel Roze; Emmanuelle Apartis; Jean-Marc Trocello
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

View more
  12 in total

Review 1.  Using the shared genetics of dystonia and ataxia to unravel their pathogenesis.

Authors:  Esther A R Nibbeling; Cathérine C S Delnooz; Tom J de Koning; Richard J Sinke; Hyder A Jinnah; Marina A J Tijssen; Dineke S Verbeek
Journal:  Neurosci Biobehav Rev       Date:  2017-01-28       Impact factor: 8.989

2.  Dystonic Tremor and Spasmodic Dysphonia in Spinocerebellar Ataxia Type 12.

Authors:  Christos Ganos; Tabish A Saifee; Panagiotis Kassavetis; Roberto Erro; Amit Batla; Carla Cordivari; Kailash P Bhatia
Journal:  Mov Disord Clin Pract       Date:  2014-04-10

3.  Writer's Cramp as the First Symptom of Spinocerebellar Ataxia 14.

Authors:  Roberto Erro; Carla Cordivari; Mark J Edwards; Thomas Foltynie
Journal:  Mov Disord Clin Pract       Date:  2014-12-06

4.  Pharmacological induction of heat shock proteins ameliorates toxicity of mutant PKCγ in spinocerebellar ataxia type 14.

Authors:  Aoi Nakazono; Naoko Adachi; Hideyuki Takahashi; Takahiro Seki; Daizo Hamada; Takehiko Ueyama; Norio Sakai; Naoaki Saito
Journal:  J Biol Chem       Date:  2018-08-09       Impact factor: 5.157

Review 5.  Myoclonus-Ataxia Syndromes: A Diagnostic Approach.

Authors:  Malco Rossi; Sterre van der Veen; Marcelo Merello; Marina A J Tijssen; Bart van de Warrenburg
Journal:  Mov Disord Clin Pract       Date:  2020-11-03

6.  SCA2 presenting as a focal dystonia.

Authors:  Nan Cheng; Heather M Wied; James J Gaul; Lauren E Doyle; Stephen G Reich
Journal:  J Clin Mov Disord       Date:  2018-08-13

7.  Differential expression of striatal proteins in a mouse model of DOPA-responsive dystonia reveals shared mechanisms among dystonic disorders.

Authors:  Maria A Briscione; Ashok R Dinasarapu; Pritha Bagchi; Yuping Donsante; Kaitlyn M Roman; Anthony M Downs; Xueliang Fan; Jessica Hoehner; H A Jinnah; Ellen J Hess
Journal:  Mol Genet Metab       Date:  2021-06-02       Impact factor: 4.204

8.  Restoration of Central Programmed Movement Pattern by Temporal Electrical Stimulation-Assisted Training in Patients with Spinal Cerebellar Atrophy.

Authors:  Ying-Zu Huang; Yao-Shun Chang; Miao-Ju Hsu; Alice M K Wong; Ya-Ju Chang
Journal:  Neural Plast       Date:  2015-08-31       Impact factor: 3.599

9.  A case-control proton magnetic resonance spectroscopy study confirms cerebellar dysfunction in benign adult familial myoclonic epilepsy.

Authors:  Lili Long; Yanmin Song; Linlin Zhang; Chongyu Hu; Jian Gong; Lin Xu; Hongyu Long; Luo Zhou; Yunci Zhang; Yong Zhang; Bo Xiao
Journal:  Neuropsychiatr Dis Treat       Date:  2015-02-25       Impact factor: 2.570

10.  Genotype-phenotype correlations, dystonia and disease progression in spinocerebellar ataxia type 14.

Authors:  Viorica Chelban; Sarah Wiethoff; Bjørn K Fabian-Jessing; Nourelhoda A Haridy; Alaa Khan; Stephanie Efthymiou; Esther B E Becker; Emer O'Connor; Joshua Hersheson; Katrina Newland; Allan Thomas Hojland; Pernille A Gregersen; Suzanne G Lindquist; Michael B Petersen; Jørgen E Nielsen; Michael Nielsen; Nicholas W Wood; Paola Giunti; Henry Houlden
Journal:  Mov Disord       Date:  2018-03-30       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.